pembrolizumab,eftilagimod
novartis,merck
['tacti-002', 'immutep', '$immp']
 is pleased to provide an overview of the positive final data from part c of the tacti-002 phase ii trial to be presented in a poster presentation at the 2023 annual meeting taking place in chicago, us.
read more here: #asco2023 $imm $immp 
A late-stage clinical biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease.
(ASX: IMM, NASDAQ: IMMP)